Evaluation of compliance with injection protocols and any barriers to consistent administration
Frequently Asked Questions About GLP-3 (Reta) What is GLP-3 (Reta) used for in research?+ What purity is Koi's GLP-3 (Reta)?+ How do I reconstitute GLP-3 (Reta)?+ What is the CAS number for GLP-3 (Reta)?+ How does GLP-3 (Reta) compare with GLP-1 (Sema) and GLP-2 (Triz) as a research tool?+ Is GLP-3 (Reta) FDA-approved?+ How should GLP-3 (Reta) be stored?+ Is GLP-3 (Reta) for human use?+ Stock your lab with Koi Research-grade peptides made in the USA, third-party tested, with public lot-matched COAs
And it's available over the counter
5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg/mL 250 mcg dose = 10 units (0.1 mL) on a 100-unit insulin syringe 500 mcg dose = 20 units (0.2 mL) on a 100-unit insulin syringe Doses per vial: 20 doses at 250 mcg, or 10 doses at 500 mcg Supplies Needed (8-Week Cycle at 250 mcg/day) 3 vials BPC-157 (5 mg each) provides 60 doses, covers 56 days with margin 3 vials bacteriostatic water (30 mL each) 60 insulin syringes (2931 gauge, 100-unit) Alcohol prep pads Administration Injection Technique BPC-157 goes subcutaneous (SubQ)
It appears as a clear, deep blue liquid and is completely odorless
Sessions are typically scheduled weekly or bi-weekly, and noticeable results may appear within 4 to 6 weeks, with full benefits achieved after consistent sessions